Pharma Industrial India - Professional magazine for pharma industry suppliers and lab technology

NEWS ABOUT >

Biotechnology

Clean Rooms

Clinical Trials

Consultants

Digitalization

Drug Discovery & Development

Engineering

Global Pharma

Industrial talks

Ingredients

Lab Equipment

Logistics & Distribution

Manufacturing

Market

Outsourcing

Packaging

Quality / GMP

Regulation

Safety

Last edition

All magazines
Subscribe to our magazine

News about "ASCO 2026"

Study Finds Comparable CAR T-Cell Therapy Outcomes Across Accredited and Non-Accredited Cancer Centres

A large-scale study involving more than 6,800 lymphoma patients found that CAR T-cell therapy delivered at non-FACT accredited centres achieved outcomes comparable to accredited facilities, supporting efforts to expand access to advanced cancer treatments closer to patients’ homes.

ASCO 2026 | 30/05/2026 | By News Bureau

Bristol Myers Squibb's Mezigdomide Cuts Disease Progression Risk by Over 50 Percent in Multiple Myeloma

Bristol Myers Squibb reported Phase 3 SUCCESSOR-2 results showing that mezigdomide reduced the risk of disease progression or death by more than 50% versus standard of care in relapsed or refractory multiple myeloma, marking the first successful Phase 3 CELMoD trial presented at ASCO 2026.

ASCO 2026 | 30/05/2026 | By News Bureau

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members